Article · 20 May 2025
Review articlePublished 15 Jul 2016
Dasatinib for the treatment of chronic phase chronic myeloid leukemia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder driven by the oncogenic tyrosine kinase BCR-ABL. The discovery of the tyrosine kinase inhibitor imatinib revolutionized the management of patients with CML. However, imatinib can have significant side effects, and is not effective in all patients. The development of second-generation (dasatinib and nilotinib) and third-generation (ponatinib) tyrosine kinase inhibitors sought to address the issue of imatinib-resistance and -intolerance and furthermore, to determine if these agents are superior to imatinib. Dasatinib, a multitargeted inhibitor, is effective against most BCR-ABL kinase domain mutations resistant to imatinib and capable of inducing faster and deeper molecular responses. This article describes the development of dasatinib and documents its current clinical use in chronic phase CML.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Victoria Campbell”
- BylineArticles whose byline prints “Mhairi Copl”